Substrate specificity and transglycosylation capacity of α-L-fucosidases across GH29 assessed by bioinformatics-assisted selection of functional diversity.

Glycoside hydrolase family 29 (GH29) encompasses α-L-fucosidases, i.e. enzymes that catalyze the hydrolytic release of fucose from fucosylated glycans, including N- and O-linked glycans on proteins, and these α-L-fucosidases clearly play important roles in biology. GH29 enzymes work via a retaining exo-action mechanism, and some can catalyze transfucosylation. There is no formal subfamily division of GH29 α-L-fucosidases, but they are nonetheless divided into two subfamilies: GH29A having a range of substrate specificities and GH29B having narrower substrate specificity. However, the sequence traits that determine the substrate specificity and transglycosylation ability of GH29 enzymes are not well characterized. Here, we present a new functional map of family GH29 members based on peptide-motif clustering via CUPP (conserved unique peptide patterns) and compare the substrate specificity and transglycosylation activity of 21 representative α-L-fucosidases across the 53 CUPP groups identified. The 21 enzymes exhibited different enzymatic rates on 8 test substrates, CNP-Fuc, 2'FL, 3FL, Lewisa, Lewisx, Fuc-α1,6-GlcNAc, Fuc-α1,3-GlcNAc, and Fuc-α1,4-GlcNAc. Certain CUPP groups clearly harbored a particular type of enzymes, e.g. the majority of the enzymes having activity on Lewisa or Lewisx categorized in the same CUPP clusters. In general, CUPP was useful for resolving GH29 into functional diversity subgroups when considering hydrolytic activity. In contrast, the transglycosylation capacity of GH29 α-L-fucosidases was distributed across a range of CUPP groups. Transglycosylation thus appears to be a common trait among these enzymes and not readily predicted from sequence comparison.

Enzymatic production of a suite of human milk oligosaccharides directly in milk.

Human milk oligosaccharides (HMOs) denote specific glycans in human breast milk. They function as prebiotics, immune modulating, and antimicrobial agents in the gut of breastfed infants, and certain HMOs even promote the cognitive development of the baby. HMOs are virtually absent in cow's milk and hence in infant formula, which provides a huge incentive for identifying ways in which HMOs can be produced to improve infant formulas. Here, we show that different sialylated and fucosylated HMOs can be generated in cow's milk via different simultaneous enzymatic transglycosylation reactions catalyzed by an engineered sialidase (EC 3.2.1.18, from Trypanosoma rangeli) and an 1,2-α-L-fucosidase (EC 3.2.1.63, from Tannerella forsinthia) acting on the lactose in the milk and on casein glycomacropeptide, two types of commercially available HMOs, i.e. 2'-fucosyllactose and lacto-N-neotetraose, added to the milk. We also outline the details of the individual reactions in aqueous systems, demonstrate that the enzymatic reactions can be accomplished at 5 °C, and validate the products formed by LC-MS and NMR analysis. Enzymatic production of HMOs directly in milk provides opportunities for enriching milk and infant formulas and extends the use of enzymatic transglycosylation reactions to synthesis of HMOs in milk and eventually in other beverages.

Enzymatic production of 3'-sialyllactose in milk.

Human milk oligosaccharides (HMOs) are lactose-based glycan molecules present in human breast milk. HMOs are essentially not present in cow's milk and hence not naturally available in infant formulas. HMOs possess several health and developmentally beneficial properties, and the sialylated HMOs are thought to play a particularly important role for infant brain development. Enzymatic transsialylation directly in cow's milk, involving enzyme catalyzed transfer of sialic acid from a sialic acid donor to an acceptor, is a novel route for producing sialylated HMOs for e.g. infant formulas. The transsialidase (EC 2.4.1.-) of Trypanosoma cruzi is linked to trypanosomatid pathogenicity, but certain hydrolytic sialidases (neuraminidases), EC 3.2.1.18, from non-pathogenic organisms, can actually catalyze transsialylation. Here, we report enzymatic production of the HMO compound 3'-sialyllactose directly in cow's milk using engineeredsialidases, Tr15 and Tr16, originating from the nonpathogenic Trypanosoma rangeli. Both Tr15 and Tr16 readily catalyzed transsialylation in milk at 5 °C-40 °C using κ(kappa)-casein glycomacropeptide (cGMP) as sialyl donor substrate. Tr15 was the most efficient as this enzyme produced 1160 mg/L (1.8 mM) 3'-sialyllactose in whole milk during 10 min of reaction at 5 °C. The activation energy values, Ea, of the enzymatic transsialylation reactions were similar in milk and in buffer solutions containing cGMP and lactose. The Ea of the Tr15 catalyzed transialylation reaction in milk was 16.5 kJ/mol, which was three times lower than the Ea of Tr16 (66 kJ/mol) and of T. cruzi transsialidase (50 kJ/mol), corroborating that Tr15 was the fastest of the three enzymes and a promising candidate for potential industrial production of 3'-sialyllactose in milk. 3'sialyllactose was stable during pasteurization (30 min. at 62.5 °C) and freeze-drying.